Abstract
We investigated whether immunosuppressive therapy using methylprednisolone (mPSL) with or without cyclosporin A (CsA) could benefit patients with myelodysplastic syndrome (MDS). Eligibility criteria for this study were a clinical diagnosis of MDS with less than 5% blast in peripheral blood, less than 10% blast in bone marrow and advanced cytopenia. Among 73 patients with MDS, 18 eligible and consecutive patients (8 men and 10 women), aged 48 to 87 years (median: 66.5 years) were assigned to receive mPSL pulse therapy (1,000 mg daily for 3 consecutive days, followed by tapering oral prednisolone; n= 12) or mPSL pulse with CsA therapy (4 to 5 mg/kg administered twice daily; n= 6). Six of 18 patients (33.3%; 3 of 10 patients with RA, 2 of 6 patients with RAEB, 1 of 2 patients with CMMoL) responded to immunosuppressive therapy. Four patients responded to mPSL pulse alone, and two patients responded to mPSL pulse with CsA. One of 6 patients with hypocellular bone marrow and 5 of 12 patients with normocellular or hypercellular marrow responded to immunosuppressive therapy. No patient with myelofibrosis responded to the therapy. The duration of response ranged from 4 to 59 months (median: 14 months). Although a significant difference was observed between responders and nonresponders in the survival rate (P<0.05), no significant difference was found in clinical characteristics at entry between responders and nonresponders. In responders, mean hemoglobin levels were significantly increased (P<0.01), and the required red cell transfusion dose was significantly reduced (P<0.01). It is possible that immunosuppressive therapy might be effective for a certain subset of patients with MDS.
Similar content being viewed by others
References
Applebaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE, Thomas ED (1987) Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 15:1134–1139
Bennett JM (2000) World Health Organization classification of the acute leukaemias and myelodysplastic syndrome. Int J Hematol 72:131–133
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol 51:189–199
Bessho M, Jinnai I, Hirashima K, Saito M, Murohashi I, Ino H, Tsuji M, Fukuda M, Maruyama M, Kusumoto S, Tominaga K, Matsuda A, Kawai N, Itoh K, Sakata T, Handa A, Endo K, Toyoda A, Kobayashi Y, Kashimura T, Kawano M, Minamihisamatsu M (1994) Trilineage recovery by combination therapy with recombinant human granulocyto colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem cells 12:604–615
Biesma DH, van den Tweel JG, Verdonck LF (1997) Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79:1548–1551
Champlin R, Ho W, Gale RP (1983) Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 308:113–118
Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non–lymphocytic leukaemia and myelodysplastic syndromes. J Clin Oncol 4:1857–1864
Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Brit J Haematol 91:403–408
Ferrara F, Copia C, Annunziata M, Noto Rdi, Russo C, Palmieri S, Spasiano A, Vecchio L (1999) Complete remission of refractory anemia following a single high dose of cyclophosphamide. Ann Hematol 78:87–88
Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Heimpel H (1991) Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Eng J Med 324:1297–1304
Geary CG, Marsh JCW, Gordon-Smith EC (1996) Hypoplastic myelodysplasia (MDS). Brit J Haematol 94:579–580
Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh JCW (1999) Abnormal cytogenetic clones in patients with aplastic anemia; response to immunosuppressive therapy. Brit J Haematol 104:271–274
Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150–162
Josanova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, Hochova I (1998) Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemia without hypoplastic bone marrow. Brit J Haematol 100:304–309
Leonard EM, Raefsky E, Griffith P, Kimball J,Nienhuis AW, Young NS (1989) Cyclosporine therapy of aplastic anemia, congenital and acquired red cell aplasia. Brit J Haematol 72:278–284
Litzow MR, Kyle RA (1989) Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. Am J Hematol 32:226–229
Miescher PA, Favre H, Beris P (1991) Autoimmune myelodysplasias. Semin Haematol 28:322–330
Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Brit J Haematol 99:699–705
Motoji T, Teramura M, Takahashi M, Oshimi K, Okada M, Kusakabe K, Mizoguchi H (1990) Successful treatment of refractory anemia with high-dose methylprednisolone. Am J Hematol 33:8–12
Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA (1986) Immunological abnormalities in myelodysplastic syndromes. Serum immunoglobulins and autoantibodies. Brit J Haematol 63:143–147
Muller EW, De Wolfe JThM, Vellenga E (1993) Successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with refractory anemia. Brit J Haematol 83:171–172
Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, Kaneshige T, Mizoguchi H (1994) Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84:4257–4261
Nakao S, Takami A, Sugimori N, Ueda M, Shiobara S, Matsuda T, Mizoguchi H (1996) Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1 1501 does not predict response to antithymocyte globulin. Brit J Haematol 92:155–158
Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36–43
Nimer SD, Paquette RL, Ireland P, Resta D, Young D, Golde DW (1994) A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 22:875–880
Ohno R (1994) Differentiation therapy of myelodysplastic syndoromes with retinoic acid. Leuk Lymphoma 14:401–409
Okamoto T, Okada M, Yamada S, Takatsuka H, Wada H, Tamura A, Takemoto Y, Kakishita E (2000) Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1 1501 allele. Leukemia 14:344–346
Sulecki M, Shadduck RK, Zeigler Z (1988) Anti-thymocyte globulin for myelodysplastic syndrome (abstract). Blood 72:229A
Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B (1988) Antilymphocyte globulin for myelodysplastic syndrome?. Brit J Haematol 68:139–140
Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM (1995) Hypocellular myelodysplastic syndromes (MDS): new proposals. Brit J Haematol 91:612–617
Young NS (1992) The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood 79:1385–1392
Young NS, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A, Harmon D, Hewlett J, Fay J, Mangan K, Morrison F, Sensenbrenner L, Shadduck R, Wang W, Zaroulis C, Zuckerman K (1988) A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 72:1861–1869
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamada, T., Tsurumi, H., Kasahara, S. et al. Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol 129, 485–491 (2003). https://doi.org/10.1007/s00432-003-0477-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-003-0477-z